The stock of Akebia Therapeutics Inc (NASDAQ: AKBA) has decreased by -1.65 when compared to last closing price of 3.64.Akebia Therapeutics Inc (NASDAQ: AKBA)’s stock price has plunge by -1.65relation to previous closing price of 3.64. Despite this, the company has seen a loss of -2.45% in its stock price over the last five trading days. globenewswire.com reported 2025-06-04 that Akebia continues to publish important, clinically relevant data to further physicians’ understanding of Vafseo® (vadadustat) Akebia continues to publish important, clinically relevant data to further physicians’ understanding of Vafseo® (vadadustat)
Is It Worth Investing in Akebia Therapeutics Inc (NASDAQ: AKBA) Right Now?
Akebia Therapeutics Inc (NASDAQ: AKBA) has a higher price-to-earnings ratio of N/Ax compared to its average ratio, The 36-month beta value for AKBA is at 0.88. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The average price suggested by analysts for AKBA is N/A, which is -$5049992.6 below the current market price. The public float for AKBA is 251.57M, and currently, shorts hold a 7.35% of that float. The average trading volume for AKBA on July 01, 2025 was 5.05M shares.
AKBA’s Market Performance
AKBA’s stock has seen a -2.45% decrease for the week, with a 18.15% rise in the past month and a 86.46% gain in the past quarter. The volatility ratio for the week is 4.85%, and the volatility levels for the past 30 days are at 6.40% for Akebia Therapeutics Inc The simple moving average for the past 20 days is -2.15% for AKBA’s stock, with a 68.37% simple moving average for the past 200 days.
Analysts’ Opinion of AKBA
Many brokerage firms have already submitted their reports for AKBA stocks, with H.C. Wainwright repeating the rating for AKBA by listing it as a “Buy.” The predicted price for AKBA in the upcoming period, according to H.C. Wainwright is $8 based on the research report published on June 04, 2025 of the current year 2025.
Leerink Partners, on the other hand, stated in their research note that they expect to see AKBA reach a price target of $7. The rating they have provided for AKBA stocks is “Outperform” according to the report published on April 28th, 2025.
Jefferies gave a rating of “Buy” to AKBA, setting the target price at $6 in the report published on April 01st of the current year.
AKBA Trading at 19.00% from the 50-Day Moving Average
After a stumble in the market that brought AKBA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.16% of loss for the given period.
Volatility was left at 6.40%, however, over the last 30 days, the volatility rate increased by 4.85%, as shares surge +8.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +71.12% upper at present.
During the last 5 trading sessions, AKBA fell by -3.95%, which changed the moving average for the period of 200-days by +144.79% in comparison to the 20-day moving average, which settled at $3.66. In addition, Akebia Therapeutics Inc saw 261.91% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AKBA starting from Ostrowski Erik, who proposed sale 41,314 shares at the price of $3.67 back on Jun 30 ’25. After this action, Ostrowski Erik now owns N/A shares of Akebia Therapeutics Inc, valued at $151,622 using the latest closing price.
Malabre Richard C, the SVP, Chief Accounting Officer of Akebia Therapeutics Inc, sale 15,000 shares at $4.01 during a trade that took place back on Jun 09 ’25, which means that Malabre Richard C is holding 266,914 shares at $60,150 based on the most recent closing price.
Stock Fundamentals for AKBA
Current profitability levels for the company are sitting at:
- -0.12 for the present operating margin
- 0.68 for the gross margin
The net margin for Akebia Therapeutics Inc stands at -0.25. The total capital return value is set at -0.1. Equity return is now at value N/A, with -16.92 for asset returns.
Based on Akebia Therapeutics Inc (AKBA), the company’s capital structure generated 0.69 points at debt to capital in total, while cash flow to debt ratio is standing at -0.64. The debt to equity ratio resting at 2.2. The interest coverage ratio of the stock is -2.78.
Currently, EBITDA for the company is -13.72 million with net debt to EBITDA at -10.03. When we switch over and look at the enterprise to sales, we see a ratio of 4.78. The receivables turnover for the company is 3.0for trailing twelve months and the total asset turnover is 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.23.
Conclusion
In conclusion, Akebia Therapeutics Inc (AKBA) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
